# Einar Bjornsson

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 63 papers | 5,787 citations | 39 h-index | 66 g-index |
| 66 ext. papers | 6,569 ext. citations | 6.2 avg, IF | 5.82 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 63 | Outcome and prognostic markers in severe drug-induced liver disease. *Hepatology*, **2005**, 42, 481-9 | 11.2 | 441 |
| 62 | Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. *Hepatology*, **2008**, 47, 2003-9 | 11.2 | 294 |
| 61 | Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. *Hepatology*, **2010**, 51, 2040-8 | 11.2 | 293 |
| 60 | Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics*, **2013**, 45, 670-5 | 36.3 | 267 |
| 59 | Risk factors for idiosyncratic drug-induced liver injury. *Gastroenterology*, **2010**, 138, 2246-59 | 13.3 | 233 |
| 58 | Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. *Journal of Hepatology*, **2012**, 56, 374-80 | 13.4 | 214 |
| 57 | The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. *Hepatology*, **2011**, 54, 931-9 | 11.2 | 199 |
| 56 | Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. *Hepatology*, **2007**, 45, 1547-54 | 11.2 | 195 |
| 55 | Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. *Hepatology*, **2010**, 51, 615-20 | 11.2 | 190 |
| 54 | Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. *Nature Genetics*, **2011**, 43, 17-9 | 36.3 | 181 |
| 53 | Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. *Journal of Hepatology*, **2012**, 57, 366-75 | 13.4 | 173 |
| 52 | Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. *Scandinavian Journal of Gastroenterology*, **2008**, 43, 1232-40 | 2.4 | 151 |
| 51 | Dominant strictures in patients with primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2004**, 99, 502-8 | 0.7 | 135 |
| 50 | Hepatotoxicity by Drugs: The Most Common Implicated Agents. *International Journal of Molecular Sciences*, **2016**, 17, 224 | 6.3 | 128 |
| 49 | Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. *Hepatology*, **2010**, 52, 571-7 | 11.2 | 122 |
| 48 | Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. *Hepatology*, **2013**, 58, 1074-83 | 11.2 | 118 |
| 47 | Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. *Drug Safety*, **2010**, 33, 503-22 | 5.1 | 110 |

| | | | |
|---|---|---|---|
| 46 | Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. *Journal of Hepatology*, **1998**, 28, 426-32 | 13.4 | 110 |
| 45 | The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. *Journal of Hepatology*, **2009**, 50, 511-7 | 13.4 | 107 |
| 44 | Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. *Scandinavian Journal of Gastroenterology*, **2005**, 40, 1095-101 | 2.4 | 107 |
| 43 | Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. *Digestive and Liver Disease*, **2011**, 43, 309-13 | 3.3 | 105 |
| 42 | Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. *Scandinavian Journal of Gastroenterology*, **2005**, 40, 206-16 | 2.4 | 101 |
| 41 | Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. *American Journal of Therapeutics*, **2011**, 18, 198-205 | 1 | 96 |
| 40 | Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. *Hepatology*, **2011**, 53, 1977-85 | 11.2 | 96 |
| 39 | Drug-induced liver injury: a clinical update. *Current Opinion in Gastroenterology*, **2010**, 26, 222-6 | 3 | 95 |
| 38 | Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. *Scandinavian Journal of Gastroenterology*, **2006**, 41, 1464-72 | 2.4 | 93 |
| 37 | Drug-induced liver injury: Hyς rule revisited. *Clinical Pharmacology and Therapeutics*, **2006**, 79, 521-8 | 6.1 | 81 |
| 36 | Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. *Liver International*, **2007**, 27, 1194-201 | 7.9 | 70 |
| 35 | Coronary artery disease in patients with liver cirrhosis. *Digestive Diseases and Sciences*, **2010**, 55, 467-75 | 4 | 65 |
| 34 | Clinical characteristics and prognostic markers in disulfiram-induced liver injury. *Journal of Hepatology*, **2006**, 44, 791-7 | 13.4 | 60 |
| 33 | Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. *Scandinavian Journal of Gastroenterology*, **2010**, 45, 457-67 | 2.4 | 59 |
| 32 | Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. *Journal of Hepatology*, **2009**, 50, 388-93 | 13.4 | 59 |
| 31 | Epidemiology and risk factors for idiosyncratic drug-induced liver injury. *Seminars in Liver Disease*, **2014**, 34, 115-22 | 7.3 | 57 |
| 30 | Altered postprandial glucose, insulin, leptin, and ghrelin in liver cirrhosis: correlations with energy intake and resting energy expenditure. *American Journal of Clinical Nutrition*, **2007**, 85, 808-15 | 7 | 57 |
| 29 | Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. *Liver International*, **2012**, 32, 441-8 | 7.9 | 55 |

| | | | |
|---|---|---|---|
| 28 | Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. *Scandinavian Journal of Gastroenterology*, **2005**, 40, 1090-4 | 2.4 | 50 |
| 27 | Factors related to fatigue in patients with cirrhosis before and after liver transplantation. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 174-81, 181.e1 | 6.9 | 41 |
| 26 | Non-alcoholic fatty liver disease. *Scandinavian Journal of Gastroenterology*, **2007**, 42, 1023-30 | 2.4 | 39 |
| 25 | Fatigue is not a specific symptom in patients with primary biliary cirrhosis. *European Journal of Gastroenterology and Hepatology*, **2005**, 17, 351-7 | 2.2 | 39 |
| 24 | Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 57-63 | 6.9 | 38 |
| 23 | Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis. *Clinical Gastroenterology and Hepatology*, **2009**, 7, 346-52 | 6.9 | 38 |
| 22 | Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 245-253 | 6.1 | 35 |
| 21 | The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. *Digestive and Liver Disease*, **2014**, 46, 903-8 | 3.3 | 31 |
| 20 | Immunoglobulin G4-associated cholangitis. *Current Opinion in Gastroenterology*, **2008**, 24, 389-94 | 3 | 31 |
| 19 | Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. *Liver International*, **2014**, 34, 1488-95 | 7.9 | 28 |
| 18 | Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. *European Journal of Gastroenterology and Hepatology*, **2008**, 20, 512-8 | 2.2 | 28 |
| 17 | Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. *Gut*, **2018**, 67, 1517-1524 | 19.2 | 28 |
| 16 | Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis. *BMC Gastroenterology*, **2014**, 14, 65 | 3 | 26 |
| 15 | The natural history of drug-induced liver injury. *Seminars in Liver Disease*, **2009**, 29, 357-63 | 7.3 | 26 |
| 14 | Pregabalin as a probable cause of acute liver injury. *European Journal of Gastroenterology and Hepatology*, **2008**, 20, 1049 | 2.2 | 23 |
| 13 | Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. *BMC Gastroenterology*, **2008**, 8, 46 | 3 | 23 |
| 12 | Hepatic encephalopathy is related to anemia and fat-free mass depletion in liver transplant candidates with cirrhosis. *Scandinavian Journal of Gastroenterology*, **2013**, 48, 577-84 | 2.4 | 22 |
| 11 | Effects of duodenal lipids on gastric sensitivity and relaxation in patients with ulcer-like and dysmotility-like dyspepsia. *Digestion*, **2003**, 67, 209-17 | 3.6 | 22 |

| | | | |
|---|---|---|---|
| 10 | Pre-transplant renal impairment predicts posttransplant cardiac events in patients with liver cirrhosis. *Transplantation*, **2014**, 98, 107-14 | 1.8 | 17 |
| 9 | Hepatic encephalopathy in patients with liver cirrhosis: is there a role of malnutrition?. *World Journal of Gastroenterology*, **2008**, 14, 3438-9 | 5.6 | 17 |
| 8 | Coronary artery disease in liver cirrhosis: does the aetiology of liver disease matter?. *Journal of Hepatology*, **2009**, 51, 962-3; author reply 963-4 | 13.4 | 15 |
| 7 | Lactulose treatment for hepatic encephalopathy, gastrointestinal symptoms, and health-related quality of life. *Hepatology*, **2007**, 46, 949-50; author reply 951 | 11.2 | 13 |
| 6 | Gastrointestinal symptoms in patients with cirrhosis: a longitudinal study before and after liver transplantation. *Scandinavian Journal of Gastroenterology*, **2013**, 48, 1308-16 | 2.4 | 11 |
| 5 | Abstinence in patients with alcoholic liver cirrhosis: A follow-up study. *Hepatology Research*, **2008**, 38, 869-76 | 5.1 | 9 |
| 4 | Sclerosing cholangitis. *Current Opinion in Gastroenterology*, **2003**, 19, 270-5 | 3 | 7 |
| 3 | Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis. *Quality of Life Research*, **2016**, 25, 947-57 | 3.7 | 5 |
| 2 | Cognitive dysfunction in liver cirrhosis: does hepatitis C virus play a role?. *Journal of Gastroenterology*, **2008**, 43, 248 | 6.9 | 1 |
| 1 | Drug-Induced Liver Injury **2016**, 503-507 | | |